Literature DB >> 10383138

Activation of mitochondrial Raf-1 is involved in the antiapoptotic effects of Akt.

M Majewski1, M Nieborowska-Skorska, P Salomoni, A Slupianek, K Reiss, R Trotta, B Calabretta, T Skorski.   

Abstract

The Akt serine/threonine kinase is required for the survival of many cell types and for transformation of hematopoietic cells by the BCR/ABL oncogenic tyrosine kinase. Analysis of the potential mechanisms whereby Akt promotes survival of hematopoietic cells revealed that it induced the activity of plasma membrane and mitochondrial Raf-1 in a Ras-independent, but PKC-dependent manner. Inhibition of plasma membrane Raf-1-dependent mitogen-activated protein kinase activity had no effect on the enhanced survival of cells expressing Akt. By contrast, suppression of mitochondrial Raf-1 enzymatic activity by expression of a mitochondria-targeted Raf-1 dominant-negative mutant rendered Akt-expressing cells susceptible to apoptosis induced by growth factor deprivation and was accompanied by inhibition of BAD, but not mitogen-activated protein kinase, phosphorylation. Together, these data indicate that PKC-dependent activation of Raf-1 plays an important role in Akt-dependent antiapoptotic effects.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10383138

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  29 in total

1.  Isoform-specific localization of A-RAF in mitochondria.

Authors:  A Yuryev; M Ono; S A Goff; F Macaluso; L P Wennogle
Journal:  Mol Cell Biol       Date:  2000-07       Impact factor: 4.272

Review 2.  Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions.

Authors:  W Kolch
Journal:  Biochem J       Date:  2000-10-15       Impact factor: 3.857

3.  Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance.

Authors:  James A McCubrey; Linda S Steelman; Richard A Franklin; Steven L Abrams; William H Chappell; Ellis W T Wong; Brian D Lehmann; David M Terrian; Jorg Basecke; Franca Stivala; Massimo Libra; Camilla Evangelisti; Alberto M Martelli
Journal:  Adv Enzyme Regul       Date:  2007-03-26

Review 4.  Classical Protein Kinase C: a novel kinase target in breast cancer.

Authors:  R K Singh; S Kumar; M S Tomar; P K Verma; S P Singh; P K Gautam; A Acharya
Journal:  Clin Transl Oncol       Date:  2018-07-30       Impact factor: 3.405

5.  The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidylinositol 3-kinase and Raf.

Authors:  M S Neshat; A B Raitano; H G Wang; J C Reed; C L Sawyers
Journal:  Mol Cell Biol       Date:  2000-02       Impact factor: 4.272

Review 6.  MicroRNA and signaling pathways in gastric cancer.

Authors:  Z Zhang; Z Li; Y Li; A Zang
Journal:  Cancer Gene Ther       Date:  2014-07-25       Impact factor: 5.987

7.  hnRNP A1 nucleocytoplasmic shuttling activity is required for normal myelopoiesis and BCR/ABL leukemogenesis.

Authors:  Angela Iervolino; Giorgia Santilli; Rossana Trotta; Clara Guerzoni; Vincenzo Cesi; Anna Bergamaschi; Carlo Gambacorti-Passerini; Bruno Calabretta; Danilo Perrotti
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

Review 8.  Mitochondrial determinants of cancer health disparities.

Authors:  Aaheli Roy Choudhury; Keshav K Singh
Journal:  Semin Cancer Biol       Date:  2017-05-06       Impact factor: 15.707

9.  Phosphatidylinositol 3-kinase p85{alpha} subunit-dependent interaction with BCR/ABL-related fusion tyrosine kinases: molecular mechanisms and biological consequences.

Authors:  Shu-Yue Ren; Elisabeth Bolton; M Golam Mohi; Andrea Morrione; Benjamin G Neel; Tomasz Skorski
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

10.  Expression of erbB/HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry.

Authors:  F J Esteva; G N Hortobagyi; A A Sahin; T L Smith; D M Chin; S Y Liang; L Pusztai; A U Buzdar; S S Bacus
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.